MedTrace Logo

Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06

NCT07299253 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-12-23

No results posted yet for this study

Summary

This study aims to systematically evaluate the safety, biodistribution, dosimetry, and preliminary therapeutic potential of \[177Lu\]Lu-TEFAPI-06 through an exploratory first-in-human (FIH) trial.

Conditions

  • Metastatic Solid Tumors (Any Localization)

Interventions

DRUG

radionuclide therapy with [177Lu]Lu--TEFAPI-06

A Novel Albumin-Binding FAPI Radiopharmaceutical for Theranostics

Sponsors & Collaborators

  • Lanzhou University Second Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-16
Primary Completion
2024-08-16
Completion
2025-08-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07299253 on ClinicalTrials.gov